Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives

International Journal of Pharmaceutics

Volumn 371, Issue 1-2, 2009, Pages 106-113

  Breda, Susana A ^a   Jimenez Kairuz, Alvaro F ^a   Manzo, Ruben H ^a   Olivera, María E ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

Biopharmaceutics Classification System (BCS); Complexation; Dissolution rate; Formulation; Permeability; Solubility; Tableting

Indexed keywords

ALUMINUM CHLORIDE; CIPROFLOXACIN; NORFLOXACIN;

ARTICLE; CLASSIFICATION; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; METAL BINDING; PH; PRIORITY JOURNAL; SOLID; STOICHIOMETRY; TABLET FORMULATION;

BIOPHARMACEUTICS; CIPROFLOXACIN; DRUG COMPOUNDING; EXCIPIENTS; NORFLOXACIN; PERMEABILITY; SOLUBILITY; TABLETS;

EID: 62749183611     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.12.026     Document Type: Article

References (61)

1. Adhami Z., Wise R., Weston D., and Crump B. The pharmacokinetics and tissue penetration of norfloxacin. J. Antimicrob. Chemother. 13 (1984) 87-92
2. Ahumada A., Seeck J., Allemandi D., and Manzo R. The pH/solubility profile of norfloxacin. S. T. P. Pharm. Sci. 3 (1993) 250-253
3. Allemandi D., Alovero F., and Manzo R. Formulation of a neutral solution of ciprofloxacin upon complexation with aluminum. Il Fármaco 54 (1999) 758-760
4. Alovero F., Olivera M., and Manzo R. In vitro pharmacodynamic properties of a fluoroquinolone pharmaceutical derivative: hydrochloride of ciprofloxacin-aluminium complex. Int. J. Antimicrob. Agents 21 (2003) 446-451
5. Amidon G., Lennernäs H., Shah V., and Crison J. A theoretical basis for a Biopharmaceutics Drug Classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
6. ANMAT, 2008. In: Administración Nacional de Medicamentos Alimentos y Tecnología Médica de la República Argentina. http://www.anmat.gov.ar/a1.htm, [accessed August 2008].
7. Appelbaum P., and Hunter P. The fluoroquinolone antibacterials: past, present and future perspectives. Int. J. Antimicrob. Agents 16 (2000) 5-15
8. Balimane V., Pace E., Chong S., Zhu M., Jemal M., and Van Pelt C. A novel high-throughput automated chip-based nanoelectrospray tandem mass spectrometric method for PAMPA sample analysis. J. Pharm. Biomed. Anal. 39 (2005) 8-16
9. Behrens N., and Mendoza Diaz G. Metal complexes of the antibiotic nalidixic acid. Inorg. Chim. Acta 125 (1986) 21-26
10. Chattah A., Garro-Link Y., Monti G., Levstein P., Breda S., Manzo R., and Olivera M. NMR and IR characterization of the aluminium complex of norfloxacin and ciprofloxacin fluoroquinolones. Magn. Reson. Chem. 45 (2007) 850-859
11. ®, 1989. In Bayer Health Care. http://www.cipro.com/scripts/index.php, [accessed August 2008].
12. Ciprofloxacin, 2008. In: Clinical Pharmacology. Gold Standard Multimedia Inc. http://clinicalpharmacology.com/Forms/drugoptions.aspx?cpnum=127&aprid=1114 [accessed August 2008].
13. Ciprofloxacin, 2007. In: Food and Drug Administration. http://www.fda.gov/medwatch/SAFETY/2007/Jun_PI/Cipro_Oral_PI.pdf [accessed August 2008].
14. CPMP, 2001. Note for guidance on the investigation of bioavailability and bioequivalence. http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf, [accessed August 2008].
15. Drakopoulos A., and Ioannou P. Spectrofluorimetric study of the acid-base equilibria and complexation behavior of the fluoroquinolone antibiotics ofloxacin, norfloxacin, ciprofloxacin and pefloxacin in aqueous solution. Anal. Chim. Acta 354 (1997) 197-204
16. Fallati C., Ahumada A., and Manzo R. El perfil de solubilidad de la Ciprofloxacina en función del pH. Acta Farm. Bonaer. 13 (1994) 73-77
17. FDA, 2000. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Food and Drug Administration, Center for Drug Evaluation and Research. http://www.fda.gov/cder/guidance/3618fnl.pdf, [accessed August 2008].
18. FNA, 2000. Farmacopea Nacional Argentina 7° ed. Métodos generales de Análisis. Ministerio de Salud. ANMAT, Buenos Aires. Argentina.
19. FIP, 2008. Federation International Pharmaceutical. http://www.fip.org/www2/, [accessed August 2008].
20. Grudzień M., Król A., Paterek G., Ste{ogonek}pień K., Pluciński F., and Mazurek A. The structure-bioavailability approach in antifungal agents. Eur. J. Med. Chem. (2008) 10.1016/j.ejmech.2008.10.028
21. Issopoulos P. Spectrofluorimetric determination of trace amounts of iron (III) with norfloxacin as complexing reagent. Analyst 114 (1989) 627-639
22. Kalantzi L., Reppas C., Dressman J., Amidon G., Junginger H., Midha K., Shah V., Stavchansky S., and Barends D. Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). J. Pharm. Sci. 95 (2006) 4-14
23. Kasim N., Whitehouse M., Ramachandran C., Bermejo M., Lennernas H., Hussain A., Junginger H., Stavchansky S., Midha K., Shah V., and Amidon G. Molecular Properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1 (2002) 85-96
24. Kmetec V., Kozjek F., and Veber M. Chromatographic and permeation analysis of ciprofloxacin metal complex. Int. J. Pharm. 176 (1999) 225-230
25. Ku M. Use of the Biopharmaceutical Classification System in early drug development. AAPS J. 10 (2008) 208-212
26. LeBel M. Pharmacokinetics of oral fluoroquinolones. ISI Atlas of Sciences. Pharmacology 2 (1988) 196-201
27. Lehto P., and Kivisto K. Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob. Agents Chemother 38 (1994) 248-251
28. Lennernas H., and Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J. Pharm. Pharmacol. 57 (2005) 273-285
29. Lindenberg M., Kopp S., and Dressman J. Classification of orally administered drugs on the Word Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58 (2004) 265-268
30. Manzo, R., Mazzieri, M., Olivera, M., 2005. Preparación de complejos en estado sólido de clorhidratos de antimicrobianos fluoroquiolónicos (AMFQs) con aluminio. AR007762B1 Argentinian Patent.
31. Manzo R., Olivera M., Amidon G., Shah V., Dressman J., and Barends D. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: amitriptyline hydrochloride. J. Pharm. Sci. 95 (2006) 966-973
32. Mendoza Diaz G., and Ireta Moreno J. Synthesis and characterization of zinc mixed complexes with nalidixate anion and (N-N) donors. J. Inorg. Biochem. 54 (1994) 235-246
33. Norfloxacin, 2008. In: Clinical Pharmacology. Gold Standard Multimedia Inc. http://www.clinicalpharmacology.com/apps/product/showpics.asp?monotype=full&cpnum=445 [accessed August 2008].
34. ®, 2007. In: Food and Drug Administration. http://www.fda.gov/medwatch/SAFETY/2007/Mar_PI/Noroxin_PI.pdf, [accessed August 2008].
35. Okabayashi Y., Hayashi F., Terui Y., and Kitagawa T. Studies on the interaction of pyridine carboxylic acids with metals. Chem. Pharm. Bull. 40 (1992) 692-696
36. Olivera M., Allemandi D., and Manzo R. Velocidad de disolución intrínseca y permeabilidad intestinal de complejos metálicos de norfloxacino y ciprofloxacino en relación a la formulación de comprimidos. Acta Farm. Bon. 10 (2000) 251-256
37. Olivera M., Bistoni A., Anun H., Salinas A., and Manzo R. Ototopic ciprofloxacin in a glycerin vehicle for the treatment of acute external otitis. Ear Nose Throat J. 83 625-630 (2004) 638
38. Olivera M., Mazzieri M., and Manzo R. New pharmaceutical derivatives of fluoroquinolones. Hydrochlorides of aluminium complexes of ciprofloxacin and norfloxacin. S. T. P. Pharm. Sci. 10 (2000) 51-256
39. Rodríguez-Ibañez M., Nalda Molina R., Montalar-Montero M., Bermejo Merino M., and Garrigues T. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. Eur. J. Pharm. Biopharm. 55 (2003) 241-246
40. Ross D., Elkinton S., and Riley C. Physicochemical characterization of the fluoroquinolone antimicrobials. IV. 1-octanol/water partition coefficients and their relationships to structure. Int. J. Pharm. 88 (1992) 379-389
41. Ross D., and Riley C. Aqueous solubilities of some variously substituted quinolone antimicrobials. Int. J. Pharm. 63 (1990) 237-250
42. Ross D., and Riley C. Physicochemical properties of the fluoroquinolone antimicrobials. III. Complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility. Int. J. Pharm. 87 (1992) 203-213
43. Ruana L., Chena S., Yua B., Zhua D., Cordello G., and Qiu S. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur. J. Med. Chem. 41 (2006) 605-610
44. Sakai M., Hara A., Anjo S., and Nakamura M. Comparison of the complexation fluoroquinolone antimicrobials with metal ions by nuclear magnetic resonance spectroscopy. J. Pharm. Biomed. Anal. 18 (1999) 1057-1067
45. Sanchez Navarro A., Martínez Cabarga M., and Domínguez Gil Hurle A. Oral absorption of ofloxacin administered together with aluminum. Antimicrob. Agents Chemother. 38 (1994) 2510-2512
46. Shaikh A., Giridhar R., and Yadav M. Bismuth-norfloxacin complex: synthesis, physicochemical and antimicrobial evaluation. Int. J. Pharm. 332 (2007) 24-30
47. Shimada J., Shiba K., Oguma T., Miwa H., Yoshimura Y., Nishikawa T., Okabayashi Y., Kitagawa T., and Yamamoto S. Effect of antiacid on absorption of the quinolone lomefloxacin. Antimicrob Agents Chemother. 36 (1992) 1219-1224
48. Tanaka M., Kurata T., Fujisawa C., Ohshima Y., Aoki H., Okazaki O., and Hakusiu H. Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide. Antimicrob. Agents Chemother. 37 (1993) 2173-2178
49. Volpe D. Permeability classification of representative fluoroquinolones by a cell culture method. A. A. P. S. Pharm. Sci. 6 (2004) 1-6
50. Wakita K., Yoshimoto M., Miyamoto S., and Watanabe H. A method for calculation of the aqueous solubility of organic compounds by using new fragment solubility constants. Chem. Pharm. Bull. 34 (1986) 4663-4681
51. Wallis S., Gahan L., Charles B., Hambley T., and Duckworth P. Copper (II) complexes of the fluoroquinolone antimicrobial ciprofloxacin. Synthesis, X-ray structural characterization, and potentiometric study. J. Inorg. Biochem. 62 (1996) 1-16
52. Wei H., Dalton C., Di Maso M., Kanfer I., and Löbenberg R. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur. J. Pharm. Biopharm. 69 (2008) 1046-1056
53. WHO, 2005. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf, [accessed August 2008].
54. WHO, 2007. Model list of essential medicines. http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf, [accessed August 2008].
55. Wu C., and Benet Z. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
56. Yu L., Amidon G., Polli J., Zhao H., Mehta M., Conner D., Shah V., Lesko L., Chen M., Lee V., and Hussain A. Biopharmaceutics Classification System: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
57. Yu X., Zipp G., and Ray Davison G. The effect of temperature and pH on the solubility of quinolone compounds: estimation of heat of fusion. Pharm. Res. 11 (1994) 522-527
58. Žakelj S., Berginc K., Uršič D., and Kristl A. Influence of metal cations on the solubility of fluoroquinolones. Pharmacie 62 (2007) 318-320
59. Žakelj S., Šturm K., and Kristl A. Ciprofloxacin permeability and its active secretion through rat small intestine in vitro. Int. J. Pharm. 313 (2006) 175-180
60. Zhao Y., Abraham M., Lee J., Hersey A., Luscombe C., Beck G., Sherborne B., and Cooper I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 19 (2002) 1446-1457
61. Zhu C., Jiang L., Chen T., and Hwang K. Comparative study of artificial membrane permeability assay for high throughput profiling of drug absorption potential. Eur. J. Med. Chem. 37 (2002) 399-407